Medicare Enrolled
Dr. Naim Nazha, M.D.
Medical Oncology · Northfield, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Nazha from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Nazha?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Nazha
Dr. Naim Nazha is a medical oncology specialist in Northfield, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Nazha performed 179,721 Medicare services across 4,621 unique beneficiaries.
Between the years covered by Open Payments, Dr. Nazha received a total of $2,517 from 46 pharmaceutical and/or device companies across 124 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Nazha is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 2% volume in NJ
$2,517 industry payments
Medicare Practice Summary
Medicare Utilization ↗179,721
Medicare services
Top 2% in NJ for medical oncology
4,621
Unique beneficiaries
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~8,986 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Filgrastim injection (Zarxio) for white blood cells An injection of the biosimilar medication filgrastim-sndz (Zarxio) with a dosage of 1 microgram. |
46,920 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 34,600 | $43 | $115 |
| Denosumab injection (Prolia/Xgeva) | 19,860 | $18 | $36 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
15,680 | $6 | $28 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
12,278 | $0 | $1 |
| Rituximab-pvvr biosimilar injection, 10 mg An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose. |
8,380 | $23 | $178 |
| Injection, granisetron hydrochloride, 100 mcg | 7,931 | $0 | $12 |
| Anti-nausea injection (Aloxi/palonosetron) | 3,330 | $1 | $50 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
2,940 | $8 | $18 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
2,914 | $8 | $35 |
| Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 2,735 | $2 | $15 |
| 5% dextrose/water (500 ml = 1 unit) | 2,735 | $1 | $3 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
2,353 | $71 | $146 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
2,296 | $25 | $125 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
1,874 | $12 | $70 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
1,605 | $11 | $100 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
1,302 | $1 | $3 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
1,133 | $1 | $8 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
1,087 | $14 | $75 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
1,000 | $0 | $2 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
971 | $0 | $12 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
939 | $54 | $200 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
742 | $117 | $460 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
677 | $17 | $75 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
677 | $1 | $2 |
| Pegfilgrastim-cbqv injection An injection of pegfilgrastim-cbqv, a biosimilar medication, administered at a dose of 0.5 mg. |
624 | $104 | $900 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
611 | $101 | $146 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
386 | $25 | $100 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
300 | $18 | $100 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
218 | $2 | $3 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
129 | $58 | $200 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
124 | $6 | $239 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
121 | $28 | $200 |
| Prothrombin time test (blood clotting) A laboratory test that measures how long it takes for blood to clot. This procedure evaluates the body's coagulation process. |
72 | $4 | $20 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
51 | $80 | $200 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
49 | $19 | $70 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
39 | $130 | $256 |
| New patient office visit, complex (60-74 min) | 38 | $190 | $322 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
4.3% high complexity
87.7% medium
8.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,517
Total received (2018-2024)
Avg $360/year across 7 years
Top 35% in NJ for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
46
Companies
124
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,331 (92.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$186 (7.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$891
2023
$351
2022
$217
2021
$275
2020
$274
2019
$329
2018
$179
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
SHIELD THERAPEUTICS INC
$283
Tempus AI, Inc
$110
E.R. Squibb & Sons, L.L.C.
$86
Exelixis Inc.
$72
Karyopharm Therapeutics Inc.
$64
AstraZeneca Pharmaceuticals LP
$37
Rigel Pharmaceuticals, Inc.
$34
Novartis Pharmaceuticals Corporation
$34
Immunocore Limited
$32
ABBVIE INC.
$31
ADC Therapeutics America, Inc.
$23
Janssen Biotech, Inc.
$20
Blueprint Medicines Corporation
$18
BeiGene USA, Inc.
$17
SERVIER PHARMACEUTICALS LLC
$16
GENZYME CORPORATION
$14
Top 3 companies account for 53.7% of 2024 payments
All-time payments by company (2018-2024) ›
SHIELD THERAPEUTICS INC
$283
Celltrion USA Inc.
$147
E.R. Squibb & Sons, L.L.C.
$141
Janssen Biotech, Inc.
$124
Tempus AI, Inc
$110
BeiGene USA, Inc.
$106
Exelixis Inc.
$102
Genentech USA, Inc.
$102
Seagen Inc.
$99
GlaxoSmithKline, LLC.
$88
Pharmacyclics LLC, An AbbVie Company
$83
ASD SPECIALTY HEALTHCARE, LLC
$77
Amgen Inc.
$75
ABBVIE INC.
$75
Karyopharm Therapeutics Inc.
$64
Bayer HealthCare Pharmaceuticals Inc.
$57
SERVIER PHARMACEUTICALS LLC
$50
Sysmex Inostics Inc
$46
EMD Serono, Inc.
$44
PFIZER INC.
$42
GENZYME CORPORATION
$42
Astellas Pharma US Inc
$40
Teva Pharmaceuticals USA, Inc.
$39
AstraZeneca Pharmaceuticals LP
$37
Rigel Pharmaceuticals, Inc.
$34
Novartis Pharmaceuticals Corporation
$34
Immunocore Limited
$32
Dova Pharmaceuticals
$30
Secura Bio, Inc.
$29
EISAI INC.
$27
Lilly USA, LLC
$27
ADC Therapeutics America, Inc.
$23
Ipsen Biopharmaceuticals, Inc
$23
Stemline Therapeutics Inc.
$20
AbbVie, Inc.
$18
Blueprint Medicines Corporation
$18
Eisai Inc.
$17
AbbVie Inc.
$14
Organon LLC
$14
Aadi Bioscience, Inc.
$14
Fresenius Kabi USA, LLC
$13
Janssen Pharmaceuticals, Inc
$12
Gilead Sciences, Inc.
$12
ARRAY BIOPHARMA INC
$12
Merck Sharp & Dohme Corporation
$12
Helsinn Therapeutics (U.S.), Inc.
$12
Top 3 companies account for 22.7% of all-time payments
Associated products mentioned in payments ›
ACCRUFER · AKYNZEO · AYVAKIT · Avastin · BENDEKA · BLENREP · BRAFTOVI · BRUKINSA · CABOMETYX · CARVYKTI · COPIKTRA · CYRAMZA · Cabometyx · DARZALEX · Doptelet · ELIQUIS · ERLEADA · Erleada · FARYDAK · Fyarro · IBRANCE · IMBRUVICA · IMFINZI · Imbruvica · KIMMTRAK · KISQALI · LUPRON DEPOT · Lenvima · Nexavar · OJJAARA · ONTRUZANT · OPDIVO · OPDUALAG · Orserdu · Perjeta · Rezlidhia · SARCLISA · SOMATULINE DEPOT · Sodium Chloride · Stivarga · TECENTRIQ · Tibsovo · VEGZELMA · VENCLEXTA · VERZENIO · Venclexta · Voranigo · XARELTO · XPOVIO · XT CDX · XTANDI
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (93%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
1
Per 100K population
0.4
County median income
$76,819
Nearest hospital
SHORE MEDICAL CENTER
4.4 mi
4.4 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Nazha is a mixed practice specialist, with above-average Medicare volume (top 2% in NJ), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Nazha experienced with filgrastim injection (zarxio) for white blood cells?
Based on Medicare claims data, Dr. Nazha performed 46,920 filgrastim injection (zarxio) for white blood cells services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Nazha receive payments from pharmaceutical companies?
Yes. Dr. Nazha received a total of $2,517 from 46 companies across 124 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Nazha's costs compare to other medical oncologists in Northfield?
Dr. Nazha's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Nazha) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Northfield
Browse medical oncologists in Northfield ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in NJ
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in NJ
Which NJ medical oncologists receive the most from drug and device companies.
By company
SHIELD THERAPEUTICS INC Payments to Doctors
See all physicians who received payments from SHIELD THERAPEUTICS INC.
By company
Celltrion USA Inc. Payments to Doctors
See all physicians who received payments from Celltrion USA Inc.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology